Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines

Abu-hadid, Mahmoud M.; Wilkes, John D.; El-Akawi, Zeyad; Pendyala, Lakshmi; Perez, Raymond P.

doi:10.1016/s0304-3835(97)00255-3

Cited by 26 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported HSPD1 was overexpression in 3 different cell model systems including cisplatin-resistant ovarian cancer, oxaliplatin-resistant ovarian cancer, and cisplatin-resistant bladder cancer [27]. Work by our group also showed that HSPD1 was overexpressed in cisplatin-resistant ovarian cancer cell line COC1/DDP.…”

Section: Discussionsupporting

confidence: 57%

iTRAQ Quantitative Analysis of Multidrug Resistance Mechanisms in Human Gastric Cancer Cells

Zhang

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a major obstacle towards a successful treatment of gastric cancer. However, the mechanisms of MDR are intricate and have not been fully understood. To elucidate the molecular mechanisms of MDR in gastric cancer, we employed the proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by LC-MS/MS, using the vincristine-resistant SGC7901/VCR cell line and its parental SGC7901 cell line as a model. In total, 820 unique proteins were identified and 91 proteins showed to be differentially expressed in SGC7901/VCR compared with SGC7901. Several differentially expressed proteins were further validated by western blot analysis. Furthermore, the association of MVP, one of the highly expressed proteins in SGC7901/VCR, with MDR was verified. Our study is the first application of iTRAQ technology for MDR mechanisms analysis in gastric cancer, and many of the differentially expressed proteins identified have not been linked to MDR in gastric cancer before, which showed the value of this technology in identifying differentially expressed proteins in cancer.

show abstract

Section: Discussionsupporting

confidence: 57%

iTRAQ Quantitative Analysis of Multidrug Resistance Mechanisms in Human Gastric Cancer Cells

Zhang

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Ovarian and bladder cancer Induction of chemoresistance to oxaliplatin and cisplatin [104] Colorectal cancer Enhancement of drug sensitivity to 5-FU by inhibiting HSP60 [104] HSP70…”

Section: Hsp40mentioning

confidence: 99%

“…The epigenetic inactivation of DnaJD1, observed in malignant pediatric brain tumors, further indicated for its potential role in disease pathogenesis and chemotherapeutic resistance [103]. HSP60 is highly expressed in oxaliplatin-and cisplatin-resistant ovarian and bladder cancer cells compared to the nonresistant cancer cells [104]. Notably, inhibition of HSP60 enhanced the drug sensitivity of 5-FU-resistant colorectal cancer cells, suggesting that HSP60 may play an important role in 5-FU resistance [104].…”

Section: Hsp40mentioning

confidence: 99%

“…HSP60 is highly expressed in oxaliplatin-and cisplatin-resistant ovarian and bladder cancer cells compared to the nonresistant cancer cells [104]. Notably, inhibition of HSP60 enhanced the drug sensitivity of 5-FU-resistant colorectal cancer cells, suggesting that HSP60 may play an important role in 5-FU resistance [104]. However, more investigations are needed to investigate for the role of HSP40 and HSP60 in exerting cellular resistance against chemotherapeutic agents.…”

Section: Hsp40mentioning

confidence: 99%

See 1 more Smart Citation

Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy

Yun

Kim

Lim

et al. 2019

Cells

184

144

View full text Add to dashboard Cite

Heat shock proteins (HSPs) constitute a large family of molecular chaperones classified by their molecular weights, and they include HSP27, HSP40, HSP60, HSP70, and HSP90. HSPs function in diverse physiological and protective processes to assist in maintaining cellular homeostasis. In particular, HSPs participate in protein folding and maturation processes under diverse stressors such as heat shock, hypoxia, and degradation. Notably, HSPs also play essential roles across cancers as they are implicated in a variety of cancer-related activities such as cell proliferation, metastasis, and anti-cancer drug resistance. In this review, we comprehensively discuss the functions of HSPs in association with cancer initiation, progression, and metastasis and anti-cancer therapy resistance. Moreover, the potential utilization of HSPs to enhance the effects of chemo-, radio-, and immunotherapy is explored. Taken together, HSPs have multiple clinical usages as biomarkers for cancer diagnosis and prognosis as well as the potential therapeutic targets for anti-cancer treatment.

show abstract

“…One of proteins suspected of participation in development of resistance to chemotherapeutics is Hsp60. Increased expression of this protein was correlated to resistance to cisplatin in various ovarian cancer cell lines [39]. A weak response or even resistance to chemotherapy in ovarian cancer cells also results from increased Hsp27 expression [40].…”

Section: Discussionmentioning

confidence: 99%

Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer

Bodzek

Partyka

Damasiewicz-Bodzek

2014

Journal of Ovarian Research

View full text Add to dashboard Cite

BackgroundThe aim of this study was to evaluate the concentrations of IgG antibodies against Hsp60 and Hsp65 in sera of patients with ovarian cancer at various stages of clinical progress and for different histopathological types of disease.MethodsSerum samples from 149 patients with ovarian carcinoma and 80 healthy women were investigated. The concentrations of anti-Hsp60 and anti-Hsp65 antibodies were determined using the enzyme-linked immunosorbent assay technique.ResultsThe mean concentrations of anti-Hsp60 and anti-Hsp65 antibodies in the patients with ovarian cancer did not differ significantly from the mean levels in healthy women. Analysis in relation to the clinical progression stage showed that the concentrations of these antibodies were higher when the neoplastic process was less advanced and at early stages significantly higher than in control group. Mean concentrations of both antibodies were not significantly different in relation to the histological type of the ovarian cancer. The use of chemotherapy as a primary anticancer treatment did not cause a significant change in the concentration of anti-Hsp60 antibodies, but the mean level of anti-Hsp65 after this treatment was significantly higher than in control group.ConclusionsThe immunological response to Hsp60/65 is increased in early clinical stages of ovarian cancer and the level of anti-hsp60/65 antibodies may be then a helpful diagnostic marker. Even antibodies against highly homologous Hsps may be cross-reactive only partially and differ by some functional properties.

show abstract

Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines

Cited by 26 publications

References 14 publications

iTRAQ Quantitative Analysis of Multidrug Resistance Mechanisms in Human Gastric Cancer Cells

iTRAQ Quantitative Analysis of Multidrug Resistance Mechanisms in Human Gastric Cancer Cells

Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy

Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer

Contact Info

Product

Resources

About